Literature DB >> 8082307

Soluble CD8 and CD25 in serum of patients after heart transplantation.

P L Wijngaard1, A Van der Meulen, F H Gmelig Meyling, N De Jonge, H J Schuurman.   

Abstract

To evaluate the diagnostic value of serum cytokine levels and cytokine receptor levels in the diagnosis of acute rejection after heart transplantation, we measured soluble CD8 and soluble CD25 in the serum of heart transplant recipients. The results were compared with endomyocardial biopsy (EMB) histopathology, lymphocyte activation by morphologic inspection of peripheral blood cells (cytoimmunologic monitoring), clinically manifested infections, and the maintenance immunosuppressive therapy. Significantly increased levels were observed in cases of lymphocyte activation in cytoimmunologic monitoring indicative of either rejection or infection. In clinically documented cytomegalovirus (CMV), bacterial, and Pneumocystis carinii infections, increased levels of soluble CD25 were observed. Soluble CD8 was only increased in a single case of P. carinii infection. A statistically significant correlation was calculated between the levels of soluble CD8 and whole blood cyclosporin A level. Considering chemotherapy, the levels of soluble CD8 showed an inverse correlation with the daily dosage of azathioprine. In conclusion, the levels of soluble CD8 and CD25 are associated with lymphocyte activation in peripheral blood, but do not differentiate between lymphocyte activation indicative of rejection or infection. No relationship was observed between levels of soluble CD8 and CD25, and EMB histopathology. Therefore, the assessment of these two cell products has no diagnostic potential for monitoring acute rejection after heart transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8082307      PMCID: PMC1534859          DOI: 10.1111/j.1365-2249.1994.tb06117.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Elevated titers of cell-free interleukin-2 receptor in serum and cerebrospinal fluid specimens of patients with acquired immunodeficiency syndrome.

Authors:  K K Sethi; H Näher
Journal:  Immunol Lett       Date:  1986-10       Impact factor: 3.685

2.  Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival.

Authors:  D K Wagner; J Kiwanuka; B K Edwards; L A Rubin; D L Nelson; I T Magrath
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

3.  Enumeration of transferrin-receptor-expressing lymphocytes as a potential marker for rejection in human cardiac transplant recipients.

Authors:  T Mohanakumar; K Hoshinaga; N L Wood; S Szentpetery; R R Lower
Journal:  Transplantation       Date:  1986-12       Impact factor: 4.939

4.  High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma.

Authors:  C H Pui; S H Ip; P Kung; R K Dodge; C W Berard; W M Crist; S B Murphy
Journal:  Blood       Date:  1987-09       Impact factor: 22.113

5.  Plasma interleukin 2 receptor levels in renal allograft recipients.

Authors:  R B Colvin; T C Fuller; L MacKeen; P C Kung; S H Ip; A B Cosimi
Journal:  Clin Immunol Immunopathol       Date:  1987-05

6.  High serum levels of soluble interleukin-2 receptors in sarcoidosis.

Authors:  G Semenzato; A Cipriani; L Trentin; R Zambello; M Masciarelli; F Vinante; M Chilosi; G Pizzolo
Journal:  Sarcoidosis       Date:  1987-03

7.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

8.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

9.  Cytoimmunological monitoring in acute rejection and viral, bacterial or fungal infection following transplantation.

Authors:  W Ertel; H Reichenspurner; C Lersch; C Hammer; M Plahl; M Lehmann; B M Kemkes; G Osterholzer; B Reble; B Reichart
Journal:  J Heart Transplant       Date:  1985 Jul-Aug

10.  Spontaneous release of the Leu-2 (T8) molecule from human T cells.

Authors:  J Fujimoto; S Levy; R Levy
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  1 in total

1.  Serum concentrations of soluble HLA-class I and CD8 forms in patients with viral hepatic disorders.

Authors:  M Hagihara; T Shimura; K Takebe; B Munkhbat; K Hosoi; T Kagawa; N Watanabe; S Matsuzaki; K Yamamoto; K Sato; K Tsuji
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.